论文部分内容阅读
目的评估吉非替尼治疗终末期(PS评分≥3分)非小细胞肺癌(NSCLC)的临床效果和生活质量改善情况。方法 2008年5月-2010年6月共收治终末期NSCLC患者40例,其中19例患者采用吉非替尼治疗(治疗组),21例采用支持治疗+中药治疗(对照组)。结果治疗6个月后,治疗组19例患者中,CR1例,PR5例,SD10例,PD3例。治疗组有效率为31.5%(6/19),临床受益率为84.2%(16/19)。对照组21例中,SD5例,PD16例,无CR。对照组有效率为23.8%(5/21),临床受益率为23.8%(5/21)。两组间有效率和临床受益率比较,差异均有统计学意义(P<0.05)。治疗组中位生存期为13.2个月,对照组中位生存期为4.5个月。结论吉非替尼可延长NSCLC患者的生存期,改善其生活质量。
Objective To assess the clinical efficacy and quality of life of non-small cell lung cancer (NSCLC) treated with gefitinib in the end-stage (PS score ≥3). Methods From May 2008 to June 2010, 40 patients with end-stage NSCLC were treated, of which 19 patients were treated with gefitinib (treatment group) and 21 patients were treated with supportive therapy + Chinese medicine (control group). Results After 6 months of treatment, 19 patients in the treatment group included 1 CR, 5 PR, 10 SD, and 3 PD. The effective rate in the treatment group was 31.5% (6/19) and the clinical benefit rate was 84.2% (16/19). In the control group, there were 5 cases of SD, 16 cases of PD, and no CR. The effective rate in the control group was 23.8% (5/21) and the clinical benefit rate was 23.8% (5/21). There was significant difference between the two groups in the efficiency and clinical benefit rate (P<0.05). The median survival time was 13.2 months in the treatment group and 4.5 months in the control group. Conclusion Gefitinib can prolong the survival of patients with NSCLC and improve their quality of life.